Sermorelin (10 mg Vial) Dosage Protocol
Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It was the first GHRH analog approved in the US (for pediatric GH deficiency) and stimulates endogenous pulsatile GH secretion while preserving normal feedback regulation.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once daily, before sleep
| Week | Daily Dose | U-100 Units | Volume (mL) | Notes |
|---|---|---|---|---|
| Weeks 1–4 | 200 mcg | 6 units | 0.060 mL | Starting dose |
| Weeks 5–8 | 300 mcg | 9 units | 0.090 mL | |
| Weeks 9–16 | 400–500 mcg | 12–15 units | 0.12–0.15 mL | Target range |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved.
- Refrigerate at 2–8°C; use within 28 days.
Supplies Planning
| Item | 12 Weeks | 24 Weeks |
|---|---|---|
| Sermorelin vials (10 mg each) | 4–5 vials | 8–10 vials |
| Insulin syringes (30–50 unit) | 84 | 168 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3–4 × 10 mL |
| Alcohol swabs | 2 × 100-pack | 3 × 100-pack |
Mechanism of Action
Sermorelin is GHRH(1-29), the biologically active N-terminal fragment of endogenous GHRH. It binds to GHRH receptors in the anterior pituitary and stimulates the synthesis and pulsatile secretion of growth hormone. Crucially, it preserves the normal physiological feedback mechanism — as IGF-1 rises, somatostatin (the GH suppressor) is released, naturally limiting GH excess.
This feedback preservation is a key advantage of sermorelin over exogenous HGH: the body regulates its own response, making it much harder to chronically oversuppress the GH axis or produce supraphysiological IGF-1 concentrations. Clinical use prior to market withdrawal showed meaningful improvements in body composition, sleep quality, and GH biomarkers over 3–6 month protocols.
Research Findings & Safety Profile
- First GHRH analog approved by the FDA (for pediatric GH deficiency); market withdrawn not for safety but for commercial reasons when synthetic GH became dominant.
- Preserves IGF-1 negative feedback — cannot produce supraphysiological GH like exogenous HGH.
- Clinical studies: bedtime subcutaneous injection leverages natural nocturnal GH pulse for optimal efficacy.
- Reported in clinical practice: improvements in body composition, sleep architecture, and energy in adult GH insufficiency.
- Possible effects: injection-site reactions (~17% in prescribing literature), headache, flushing (rare <1%), transient hypothyroidism (~6.5%).
- Thyroid monitoring recommended in extended protocols per clinical prescribing guidelines.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months | Dry, dark conditions |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days | Avoid freeze-thaw; protect from light |